Search

Pingda Ren

age ~55

from San Diego, CA

Also known as:
  • Ken Pingda
  • Ren Pingda
Phone and address:
5534 Havenridge Way, San Diego, CA 92130
858 888-0420

Pingda Ren Phones & Addresses

  • 5534 Havenridge Way, San Diego, CA 92130 • 858 888-0420
  • 4148 Twilight Rdg, San Diego, CA 92130 • 858 481-5397
  • 11228 Vista Sorrento Pkwy, San Diego, CA 92130 • 858 481-5397
  • 176 Union Rd, Buffalo, NY 14221
  • Williamsville, NY
  • Slingerlands, NY
  • 5534 Havenridge Way, San Diego, CA 92130 • 858 481-5397

Work

  • Company:
    Wellspring biosciences
    May 2012
  • Address:
    Greater San Diego Area
  • Position:
    Senior vp of chemistry, co-founder

Education

  • School / High School:
    Fudan University
    1985 to 1997

Skills

Chemistry • Drug Discovery • Drug Development • Biotechnology • Medicinal Chemistry • High Throughput Screening • Protein Chemistry • Biochemistry • Drug Design • In Vivo • Organic Chemistry • Lead Change • Purification • Molecular Biology • Lifesciences • Cell • Research • Oncology • Assay Development • Organic Synthesis • Elisa • In Vitro • Lc Ms • Cell Biology • Immunology • Cell Culture • Cancer • Pharmacology • Cheminformatics

Industries

Biotechnology
Name / Title
Company / Classification
Phones & Addresses
Pingda Ren
Vice President Of Chemistry
Intellikine, Inc
Mfg Pharmaceutical Preparations · Nonclassifiable Establishments
10931 N Torrey Pne Rd, La Jolla, CA 92037
858 768-6500

Us Patents

  • Compounds And Compositions As Protein Kinase Inhibitors

    view source
  • US Patent:
    7371750, May 13, 2008
  • Filed:
    Jul 29, 2004
  • Appl. No.:
    10/909227
  • Inventors:
    Taebo Sim - San Diego CA, US
    Hyun Soo Lee - San Diego CA, US
    Pingda Ren - San Diego CA, US
    Qiang Ding - San Diego CA, US
    Guobao Zhang - San Diego CA, US
    Yi Liu - San Diego CA, US
    Xia Wang - San Diego CA, US
    Tetsuo Uno - San Diego CA, US
    Bing Li - San Diego CA, US
    Lintong Li - San Diego CA, US
    Nathanael Schiander Gray - San Diego CA, US
    Shuli You - San Diego CA, US
  • Assignee:
    IRM LLC - Hamilton
  • International Classification:
    A61K 31/5355
    A61K 31/53
    A61K 31/497
    A61K 31/513
    C07D 413/12
    C07D 253/065
    C07D 487/04
    C07D 413/14
    A61P 35/00
    C07D 471/04
  • US Classification:
    5142342, 514242, 51425216, 5142621, 544112, 544118, 544182, 544256, 544279, 544 81
  • Abstract:
    The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, Bmx, c-Raf, Csk, Fes, FGFR, Flt3, Ikk, IR, JNK, Lck, Mkk, PKC, PKD, Rsk, SAPK, Syk, Trk, BTK, Src, EGFR, IGF, Mek, Ros and Tie2 kinases.
  • Compounds And Compositions As Protein Kinase Inhibitors

    view source
  • US Patent:
    7423038, Sep 9, 2008
  • Filed:
    Jun 23, 2005
  • Appl. No.:
    11/570661
  • Inventors:
    Pingda Ren - San Diego CA, US
    Xia Wang - San Diego CA, US
    Nathanael Schiander Gray - Boston MA, US
    Yi Liu - San Diego CA, US
    Taebo Sim - Chestnuthill MA, US
  • Assignee:
    IRM LLC (a Delaware Limited Liability Corporation) - Hamilton
  • International Classification:
    A61K 31/5355
    C07D 413/10
    C07D 475/00
    A61P 35/00
  • US Classification:
    5142342, 514249, 544118, 544258
  • Abstract:
    The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders than involve abnormal activation of the Abl, Bcr-abl, Bmx, c-RAF, CSK, Fes, FGFR3, Flt3, GSK3β, IR, JNK1α 1, JNK2α 2, Lck, MKK4, MKK6, p70S6K, PDGFRα, Rsk1, SAPK2α, SAPK2β, Syk and Trkβ kinases.
  • Compounds And Compositions As Protein Kinase Inhibitors

    view source
  • US Patent:
    7589101, Sep 15, 2009
  • Filed:
    Aug 15, 2006
  • Appl. No.:
    12/063550
  • Inventors:
    Barun Okram - San Diego CA, US
    Pingda Ren - San Diego CA, US
    Nathanael S. Gray - Boston MA, US
  • Assignee:
    IRM LLC - Hamilton
    The Scripps Research Institute - La Jolla CA
  • International Classification:
    A61K 31/407
    A61K 31/4162
    A61K 31/437
    C07D 471/14
  • US Classification:
    514293, 546 82
  • Abstract:
    The invention provides a novel class of compounds of formula I, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the AbI, Bcr-AbI, Aurora-A, SGK, Tie-2, Trk-B, FGFR3, c-kit, b-RAF, c-RAF, DYRK2, Fms, Fyn and PDGFRalpha and PDGFR&bgr; kinases.
  • Compounds And Compositions As Protein Kinase Inhibitors

    view source
  • US Patent:
    7642255, Jan 5, 2010
  • Filed:
    Apr 8, 2008
  • Appl. No.:
    12/099708
  • Inventors:
    Taebo Sim - Seoul, KR
    Hyun Soo Lee - San Diego CA, US
    Pingda Ren - San Diego CA, US
    Qiang Ding - San Diego CA, US
    Yi Liu - San Diego CA, US
    Bing Li - Westborough MA, US
    Lintong Li - San Diego CA, US
    Xia Wang - San Diego CA, US
    Tetsuo Uno - San Diego CA, US
    Guobao Zhang - San Diego CA, US
    Nathanael Schiander Gray - Boston MA, US
    Shuli You - Shanghai, CN
  • Assignee:
    IRM LLC - Hamilton
  • International Classification:
    C07D 413/14
    C07D 471/04
    C07D 487/04
    A61K 31/535
    A61K 31/497
    A61K 31/519
    C07D 251/12
    A61K 31/53
    A61P 35/00
  • US Classification:
    5142342, 514241, 51425505, 51425216, 5142641, 51425214, 5142621, 544279, 544117, 544215, 544256, 544118
  • Abstract:
    The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, Bmx, c-Raf, Csk, Fes, FGFR, Flt3, Ikk, IR, JNK, Lck, Mkk, PKC, PKD, Rsk, SAPK, Syk, Trk, BTK, Src, EGFR, IGF, Mek, Ros and Tie2 kinases.
  • Compositions And Methods For Modulating C-Kit And Pdgfr Receptors

    view source
  • US Patent:
    7678792, Mar 16, 2010
  • Filed:
    Oct 16, 2007
  • Appl. No.:
    11/873196
  • Inventors:
    Donatella Chianelli - San Diego CA, US
    Christopher Cow - San Diego CA, US
    Yun He - Shanghai, CN
    Songchun Jiang - San Diego CA, US
    Xiaolin Li - San Diego CA, US
    Xiaodong Liu - San Diego CA, US
    Zuosheng Liu - San Diego CA, US
    Jon Loren - San Diego CA, US
    Valentina Molteni - San Diego CA, US
    Juliet Nabakka - Santee CA, US
    Pingda Ren - San Diego CA, US
    Taebo Sim - Seoul, KR
    Xiaodong Wang - Chapel Hill NC, US
    Shuli You - Shanghai, CN
  • Assignee:
    IRM LLC - Hamilton
  • International Classification:
    C07D 471/04
    A61K 31/4375
    A61K 31/497
    A61K 31/501
    A61K 31/5355
    A61K 31/506
    C07D 413/14
    C07D 213/69
    C07D 213/61
    C07D 213/74
    C07D 213/80
    C07C 205/06
    C07C 301/00
    C07C 255/07
    C07C 69/73
    A61P 17/10
    A61P 29/00
    A61P 3/10
    A61P 31/00
    A61P 27/14
  • US Classification:
    5142325, 514300, 51425304, 51425204, 5142345, 514275, 544362, 544238, 544127, 544331, 544 80, 544119, 546296, 546318, 546310, 546297, 546122, 568705, 558 44, 558410, 560 60
  • Abstract:
    The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFRα, PDGFRβ, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGFβ, SRC, EGFR, trkB, FGFR3, FLT3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2β, BRK, KDR, c-raf or b-raf kinase, or mutant forms thereof.
  • Compounds And Compositions As Protein Kinase Inhibitors

    view source
  • US Patent:
    7745437, Jun 29, 2010
  • Filed:
    Jun 9, 2005
  • Appl. No.:
    11/628881
  • Inventors:
    Pingda Ren - San Diego CA, US
    Xia Wang - San Diego CA, US
    Guobao Zhang - San Diego CA, US
    Qiang Ding - San Diego CA, US
    Shuli You - Shanghai, CN
    Qiong Zhang - San Diego CA, US
    Greg Chopiuk - San Diego CA, US
    Pamela A. Albaugh - Carlsbad CA, US
    Taebo Sim - San Diego CA, US
    Nathanael Schiander Gray - Boston MA, US
  • Assignee:
    IRM LLC - Hamilton
  • International Classification:
    C07D 403/04
    A61K 31/4178
  • US Classification:
    5142358, 514249, 51425202, 51425405, 514256, 544122, 544238, 544295, 544328
  • Abstract:
    The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, trkB, c-SRC, BMX, FGFR3, b-RAF, ΣΓK, Tιε2, Λχκ, θNK2α2, MKK4, c-RAF, MKK6, SAPK2α and SAPK2β kinases.
  • Compounds And Compositions As Protein Kinase Inhbitors

    view source
  • US Patent:
    7846923, Dec 7, 2010
  • Filed:
    May 11, 2007
  • Appl. No.:
    12/299687
  • Inventors:
    Pingda Ren - San Diego CA, US
    Baogen Wu - San Diego CA, US
    Guobao Zhang - San Diego CA, US
    Yongping Xie - San Diego CA, US
    Barun Okram - San Diego CA, US
    Victor Nikulin - Carlsbad CA, US
    Xia Wang - San Diego CA, US
    Ha-Soon Choi - San Diego CA, US
  • Assignee:
    IRM LLC - Hamilton
  • International Classification:
    C07D 471/00
    A61K 31/54
  • US Classification:
    5142245, 546 82
  • Abstract:
    The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, Bcr-Abl(T315I), ALK, BLK, BMX, BRK, C-kit, c-RAF, CSK, c-SRC, EGFR, Fes, FGFR3, Flt3, Fms, Fyn, IGF-1R, IR, JAK(2), JAK(3), KDR, Lck, NLK, p70S6K, PDGFRα, Ros, SAPK2α, SGK, SIK, Syk, Tie2 and TrkB kinases.
  • Substituted Pyrrolo[2,3-D]Pyrimidines And Compositions As Protein Kinase Inhibitors

    view source
  • US Patent:
    8183248, May 22, 2012
  • Filed:
    May 10, 2006
  • Appl. No.:
    11/914308
  • Inventors:
    Advait Nagle - San Diego CA, US
    Nathanael Schiander Gray - Boston MA, US
    Yi Liu - San Diego CA, US
    Pingda Ren - San Diego CA, US
    Taebo Sim - San Diego CA, US
    Shuli You - Shanghai, CN
  • Assignee:
    IRM LLC - Hamilton
  • International Classification:
    C07D 487/04
    A61K 31/519
  • US Classification:
    5142651, 544280, 544122, 51425216, 5142328
  • Abstract:
    The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of Abl, Bcr-Abl, Bmx, BTK, b-RAF, c RAF, CSK, cSRC, Fes, FGFR3, Flt3, IKKα, IKKβ, JNK1α1, JNK2α2, Lck, Met, MKK4, MKK6, p70S6K, PAK2, PDGFRα, PKA, PKCα, PKD2, ROCK-II, Ros, Rsk1, SAPK2α, SAPK2β, SAPK3, SAPK4, SGK, Syk, Tie2 and TrkB kinases.

Resumes

Pingda Ren Photo 1

Co-Founder, President And Chief Operations Officer

view source
Location:
Washington, DC
Industry:
Biotechnology
Work:
Wellspring Biosciences - Greater San Diego Area since May 2012
Senior VP of Chemistry, Co-Founder

Intellikine (acquired by Takeda Pharmaceuticals in January 2012) Jan 2007 - Apr 2012
VP of Chemistry, Co-Founder

GNF Oct 2001 - Dec 2006
Senior Research Investigator

AMRI Feb 2001 - Oct 2001
Senior Research Chemist

State University of New York at Buffalo Oct 1997 - Jan 2001
Postdoctoral Fellow
Education:
Fudan University 1985 - 1997
Skills:
Chemistry
Drug Discovery
Drug Development
Biotechnology
Medicinal Chemistry
High Throughput Screening
Protein Chemistry
Biochemistry
Drug Design
In Vivo
Organic Chemistry
Lead Change
Purification
Molecular Biology
Lifesciences
Cell
Research
Oncology
Assay Development
Organic Synthesis
Elisa
In Vitro
Lc Ms
Cell Biology
Immunology
Cell Culture
Cancer
Pharmacology
Cheminformatics

Get Report for Pingda Ren from San Diego, CA, age ~55
Control profile